Cagrilintide
Also known as: AM833, long-acting amylin analog
By GLPeptideSciences Editorial Team · How we evaluate evidence · Reviewed by Dr. George S. Watson, MD, Cardiothoracic Surgeon · Updated 2026-06-02
An investigational long-acting amylin analog studied for weight management, frequently in combination with semaglutide (the CagriSema combination).
What it is & how it works
What it is
Cagrilintide is an investigational amylin analog. Amylin is a hormone released alongside insulin that contributes to feeling full; cagrilintide is engineered to last far longer in the body.
How it is thought to work
By mimicking amylin, it acts on satiety and gastric-emptying pathways that are complementary to GLP-1 — which is why it is often studied combined with semaglutide rather than alone.
The evidence and the caveat
The combination data is the most interesting part, but it is still maturing and the compound is not approved. Treat any non-trial product as unapproved and unverified.
What it's discussed & studied for
- Obesity / weight management (investigational)
- Appetite and satiety
Discussion of a use is not a claim that it works or is approved.
Research status
Investigational, studied alone and combined with semaglutide. Human trials ongoing; not approved.
Evidence quality
Human trial data exists, especially for the combination; results are still maturing and the compound is not approved.
Dosing discussion
Doses exist only within clinical trials. No approved label exists.
Educational summary of what is discussed in the literature and community — not a dosing recommendation or medical advice.
Safety & harm reduction
Gastrointestinal effects are common in trials, similar to incretin therapies. Full profile is still being established. Not approved.
Sourcing literacy
No approved product exists. Research-market 'cagrilintide' is unapproved and unverified.
Selected literature
FAQ
What is amylin?
Amylin is a hormone co-secreted with insulin that influences satiety and gastric emptying. Cagrilintide is a long-acting analog of it.
What is CagriSema?
An investigational combination of cagrilintide with semaglutide, studied to see whether the two mechanisms add up. It is not approved.